BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 17, 2015
 |  BioCentury  |  Finance

Editors wanted

Why Deerfield picked Editas for its first gene editing investment

Deerfield Management has made an initial $20 million bet on CRISPR technology with Editas Medicine, but other gene editing companies shouldn't assume the firm is closed for business.

The firm's investment was part of Editas' $120 million series B round last week that was led by bng0, which represents multiple family offices including those of Bill Gates and was formed solely to invest in Editas. The round also included Viking Global Investors, Fidelity Management & Research, funds and accounts managed by T. Rowe Price, Google Ventures, Jennison Associates, Khosla Ventures, EcoR1 Capital, Casdin Capital, Omega Funds, Cowen Private Investments; Alexandria Venture Investments, Flagship Ventures,...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >